Currently, no simple point-of-care blood test exists for use by physicians in the emergency room department or hospital to detect the presence and severity of brain trauma.
Following a brain injury, a destructive cascade of biological events continues over hours and days that may worsen the patient’s condition. Banyan Biomarkers has discovered two protein biomarkers that rapidly appear in the blood of patients after injury. Detecting these biomarkers may provide early indications of brain trauma in patients and improve clinical outcomes. Currently, the company is evaluating two proprietary proteins, Banyan GFAPTM and Banyan UCH-L1TM that may rule out the need for CT scans in patients with suspected mild traumatic brain injury.